SCHEMBL1194563

SCHEMBL1194563

CCCCCOP(N)(=O)OCCCCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 8/20 0.58
LPAR2 Q9HBW0 6/20 0.58
LPAR1 Q92633 3/20 0.58
CYP3A4 P08684 2/20 0.54
LMNA P02545 1/20 0.46
ESR1 P03372 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CDC25A P30304 1/20 0.46
AGTR1 P30556 1/20 0.46
AKT1 P31749 1/20 0.46
ADRA1A P35348 1/20 0.46
KCNH2 Q12809 1/20 0.46
CA1 P00915 7/20 0.43
CA2 P00918 7/20 0.43
CA9 Q16790 7/20 0.43
CA12 O43570 2/20 0.41
CA3 P07451 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28954648 0.98 LPAR3 (0.61) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL17686773 0.98 LPAR3 (0.61) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL29085821 0.98 LPAR3 (0.61) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL393907 0.98 LPAR3 (0.61) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL21764574 0.98 CYP3A4 (0.58) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL9463219 0.98 LPAR3 (0.61) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL21764586 0.95 LPAR3 (0.59) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL617402 0.92 CYP3A4 (0.64) LPAR3LPAR2LPAR1CYP3A4CA1
SCHEMBL28854940 0.89 LPAR3 (0.53) LPAR3LPAR2LPAR1CYP3A4LMNA
SCHEMBL28969148 0.89 LPAR3 (0.53) LPAR3LPAR2LPAR1CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114686574-B Method and kit for detecting nucleotide large fragment deletion 厦门大学 2024-07-02 CN claimed
WO-2023198181-A1 CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION THE CHINESE UNIVERSITY OF HONG KONG (CN) 2023-10-19 WO claimed
US-11788118-B2 Method for detecting target nucleic acid sequences XIAMEN ZEESAN BIOTECH CO., LTD. (CN) 2023-10-17 US claimed
CN-111100862-B Method for detecting bacterial serotypes 厦门大学 2023-09-29 CN claimed
EP-3640340-B1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES XIAMEN ZEESAN BIOTECH CO LTD (CN) 2022-06-29 EP claimed
US-20220017949-A1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES XIAMEN ZEESAN BIOTECH CO., LTD. (CN) 2022-01-20 US claimed
US-11111522-B2 Method for detecting target nucleic acid sequences XIAMEN UNIVERSITY (CN) 2021-09-07 US claimed
WO-2021128860-A1 METHOD FOR ASYMMETRIC AMPLIFICATION OF TARGET NUCLEIC ACID 厦门大学 2021-07-01 WO claimed
WO-2021128823-A1 METHOD FOR ASYMMETRIC AMPLIFICATION OF MULIPLE TARGET NUCLEIC ACIDS 厦门大学 2021-07-01 WO claimed
US-20200140931-A1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES XIAMEN ZEESAN BIOTECH CO., LTD. (CN) 2020-05-07 US claimed
EP-3640340-A1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES Xiamen University (CN) 2020-04-22 EP claimed
US-6197944-B1 OLIGODEOXYNUCLEOTIDES INTEGRATED DNA TECHNOLOGIES, INC. 2001-03-06 US claimed
JP-3019994-B2 2000-03-15 JP claimed
WO-1989005358-A1 DNA AND RNA MOLECULES STABILIZED BY MODIFICATIONS OF THE 3'-TERMINAL PHOSPHODIESTER LINKAGE AND THEIR USE AS NUCLEIC ACID PROBES AND AS THERAPEUTIC AGENTS TO BLOCK THE EXPRESSION OF SPECIFICALLY TARGETED GENES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1989-06-15 WO claimed
US-12036295-B2 Moist wipe having enhanced dispersibility NICE-PAK PRODUCTS, INC. (US) 2024-07-16 US disclosed
WO-2024147408-A1 (R,RP)-ISOMER OF 2'-FLUORO-6'-METHYLENE CARBOCYCLIC ADENOSINE MONOPHOSPHATE PRODRUG, AND USE THEREOF IMMUNODESIGNERS CO., LTD. (KR) 2024-07-11 WO disclosed
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) 2024-04-18 US disclosed
EP-0476071-A4 EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME 1992-11-04 EP disclosed
EP-0476071-A1 EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME GILEAD SCIENCES, INC. (US) 1992-03-25 EP disclosed
WO-1990015065-A1 EXONUCLEASE-RESISTANT OLIGONUCLEOTIDES AND METHODS FOR PREPARING THE SAME GILEAD SCIENCES, INC. (US) 1990-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA LPAR3 912/4885LPAR2 681/4885LPAR1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.